Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 14/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 14/20 | 0.51 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | SGK1 | O00141 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.39 |
| ▸ | DMPK | Q09013 | 1/20 | 0.39 |
| ▸ | MYLK | Q15746 | 1/20 | 0.39 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL353533 | 0.93 | ROCK2 (0.50) | ROCK2ROCK1ATG4BMAPK1EPHX2 | |
| SCHEMBL353450 | 0.91 | ROCK2 (0.48) | ROCK2ROCK1ATG4BMAPK1EPHX2 | |
| SCHEMBL353675 | 0.90 | ROCK2 (0.49) | ROCK2ROCK1ATG4BMAPK1SGK1 | |
| SCHEMBL352518 | 0.89 | ROCK2 (0.52) | ROCK2ROCK1ATG4BMAPK1EPHX2 | |
| SCHEMBL354050 | 0.88 | ROCK1 (0.54) | ROCK2ROCK1ATG4BEPHX2SGK1 | |
| SCHEMBL353772 | 0.88 | ROCK2 (0.54) | ROCK2ROCK1ATG4BEPHX2SGK1 | |
| SCHEMBL19119346 | 0.87 | ROCK1 (0.49) | ROCK2ROCK1ATG4BMAPK1EPHX2 | |
| SCHEMBL353015 | 0.87 | ROCK2 (0.52) | ROCK2ROCK1ATG4BMAPK1EPHX2 | |
| SCHEMBL353532 | 0.86 | ROCK2 (0.54) | ROCK2ROCK1ATG4BEPHX2SGK1 | |
| SCHEMBL353537 | 0.86 | ROCK1 (0.51) | ROCK2ROCK1ATG4BEPHX2SGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | claimed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | claimed |
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | NAAA, AADAC, RPSA | ROCK2 4626/4885ROCK1 4747/4885ATG4B 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.